Compile Data Set for Download or QSAR
Report error Found 60 Enz. Inhib. hit(s) with all data for entry = 11148
TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM594971(US11584758, Compound I-57)
Affinity DataIC50: 7.90nMAssay Description:In this example, compounds of the disclosure were evaluated using a biochemical assay using the ADP-Glo technology. ADP-Glo (Promega, Madison, Wis., ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/9/2023
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM594974(US11584758, Compound I-60)
Affinity DataIC50: 8.5nMAssay Description:In this example, compounds of the disclosure were evaluated using a biochemical assay using the ADP-Glo technology. ADP-Glo (Promega, Madison, Wis., ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/9/2023
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM594934(US11584758, Compound I-20)
Affinity DataIC50: 9.90nMAssay Description:In this example, compounds of the disclosure were evaluated using a biochemical assay using the ADP-Glo technology. ADP-Glo (Promega, Madison, Wis., ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/9/2023
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM594960(US11584758, Compound I-46)
Affinity DataIC50: 10.8nMAssay Description:In this example, compounds of the disclosure were evaluated using a biochemical assay using the ADP-Glo technology. ADP-Glo (Promega, Madison, Wis., ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/9/2023
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM594957(US11584758, Compound I-43)
Affinity DataIC50: 11.2nMAssay Description:In this example, compounds of the disclosure were evaluated using a biochemical assay using the ADP-Glo technology. ADP-Glo (Promega, Madison, Wis., ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/9/2023
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM594958(US11584758, Compound I-44)
Affinity DataIC50: 11.6nMAssay Description:In this example, compounds of the disclosure were evaluated using a biochemical assay using the ADP-Glo technology. ADP-Glo (Promega, Madison, Wis., ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/9/2023
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM594967(US11584758, Compound I-53)
Affinity DataIC50: 11.7nMAssay Description:In this example, compounds of the disclosure were evaluated using a biochemical assay using the ADP-Glo technology. ADP-Glo (Promega, Madison, Wis., ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/9/2023
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM594954(US11584758, Compound I-40)
Affinity DataIC50: 12nMAssay Description:In this example, compounds of the disclosure were evaluated using a biochemical assay using the ADP-Glo technology. ADP-Glo (Promega, Madison, Wis., ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/9/2023
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM594947(US11584758, Compound I-33)
Affinity DataIC50: 13nMAssay Description:In this example, compounds of the disclosure were evaluated using a biochemical assay using the ADP-Glo technology. ADP-Glo (Promega, Madison, Wis., ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/9/2023
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM594969(US11584758, Compound I-55)
Affinity DataIC50: 13.5nMAssay Description:In this example, compounds of the disclosure were evaluated using a biochemical assay using the ADP-Glo technology. ADP-Glo (Promega, Madison, Wis., ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/9/2023
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM594970(US11584758, Compound I-56)
Affinity DataIC50: 15.7nMAssay Description:In this example, compounds of the disclosure were evaluated using a biochemical assay using the ADP-Glo technology. ADP-Glo (Promega, Madison, Wis., ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/9/2023
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM594933(US11584758, Compound I-19)
Affinity DataIC50: 16.2nMAssay Description:In this example, compounds of the disclosure were evaluated using a biochemical assay using the ADP-Glo technology. ADP-Glo (Promega, Madison, Wis., ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/9/2023
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM594965(US11584758, Compound I-51)
Affinity DataIC50: 16.7nMAssay Description:In this example, compounds of the disclosure were evaluated using a biochemical assay using the ADP-Glo technology. ADP-Glo (Promega, Madison, Wis., ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/9/2023
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM594936(US11584758, Compound I-22)
Affinity DataIC50: 17.2nMAssay Description:In this example, compounds of the disclosure were evaluated using a biochemical assay using the ADP-Glo technology. ADP-Glo (Promega, Madison, Wis., ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/9/2023
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM594972(US11584758, Compound I-58)
Affinity DataIC50: 17.2nMAssay Description:In this example, compounds of the disclosure were evaluated using a biochemical assay using the ADP-Glo technology. ADP-Glo (Promega, Madison, Wis., ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/9/2023
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM594966(US11584758, Compound I-52)
Affinity DataIC50: 17.8nMAssay Description:In this example, compounds of the disclosure were evaluated using a biochemical assay using the ADP-Glo technology. ADP-Glo (Promega, Madison, Wis., ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/9/2023
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM594944(US11584758, Compound I-30)
Affinity DataIC50: 17.9nMAssay Description:In this example, compounds of the disclosure were evaluated using a biochemical assay using the ADP-Glo technology. ADP-Glo (Promega, Madison, Wis., ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/9/2023
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM594956(US11584758, Compound I-42)
Affinity DataIC50: 18nMAssay Description:In this example, compounds of the disclosure were evaluated using a biochemical assay using the ADP-Glo technology. ADP-Glo (Promega, Madison, Wis., ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/9/2023
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM594942(US11584758, Compound I-28)
Affinity DataIC50: 18.8nMAssay Description:In this example, compounds of the disclosure were evaluated using a biochemical assay using the ADP-Glo technology. ADP-Glo (Promega, Madison, Wis., ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/9/2023
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM594955(US11584758, Compound I-41)
Affinity DataIC50: 18.9nMAssay Description:In this example, compounds of the disclosure were evaluated using a biochemical assay using the ADP-Glo technology. ADP-Glo (Promega, Madison, Wis., ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/9/2023
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM594945(US11584758, Compound I-31)
Affinity DataIC50: 19.6nMAssay Description:In this example, compounds of the disclosure were evaluated using a biochemical assay using the ADP-Glo technology. ADP-Glo (Promega, Madison, Wis., ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/9/2023
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM594949(US11584758, Compound I-35)
Affinity DataIC50: 20.1nMAssay Description:In this example, compounds of the disclosure were evaluated using a biochemical assay using the ADP-Glo technology. ADP-Glo (Promega, Madison, Wis., ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/9/2023
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM594973(US11584758, Compound I-59)
Affinity DataIC50: 20.5nMAssay Description:In this example, compounds of the disclosure were evaluated using a biochemical assay using the ADP-Glo technology. ADP-Glo (Promega, Madison, Wis., ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/9/2023
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM594952(US11584758, Compound I-38)
Affinity DataIC50: 20.8nMAssay Description:In this example, compounds of the disclosure were evaluated using a biochemical assay using the ADP-Glo technology. ADP-Glo (Promega, Madison, Wis., ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/9/2023
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM594932(US11584758, Compound I-18 | US11584758, Compound I...)
Affinity DataIC50: 21.1nMAssay Description:In this example, compounds of the disclosure were evaluated using a biochemical assay using the ADP-Glo technology. ADP-Glo (Promega, Madison, Wis., ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/9/2023
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM594953(US11584758, Compound I-39)
Affinity DataIC50: 21.7nMAssay Description:In this example, compounds of the disclosure were evaluated using a biochemical assay using the ADP-Glo technology. ADP-Glo (Promega, Madison, Wis., ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/9/2023
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM594920(US11584758, Compound I-6)
Affinity DataIC50: 22.1nMAssay Description:In this example, compounds of the disclosure were evaluated using a biochemical assay using the ADP-Glo technology. ADP-Glo (Promega, Madison, Wis., ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/9/2023
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM594932(US11584758, Compound I-18 | US11584758, Compound I...)
Affinity DataIC50: 22.7nMAssay Description:In this example, compounds of the disclosure were evaluated using a biochemical assay using the ADP-Glo technology. ADP-Glo (Promega, Madison, Wis., ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/9/2023
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM594918(US11584758, Compound I-4)
Affinity DataIC50: 22.9nMAssay Description:In this example, compounds of the disclosure were evaluated using a biochemical assay using the ADP-Glo technology. ADP-Glo (Promega, Madison, Wis., ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/9/2023
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM594935(US11584758, Compound I-21)
Affinity DataIC50: 23nMAssay Description:In this example, compounds of the disclosure were evaluated using a biochemical assay using the ADP-Glo technology. ADP-Glo (Promega, Madison, Wis., ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/9/2023
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM594931(US11584758, Compound I-17)
Affinity DataIC50: 24nMAssay Description:In this example, compounds of the disclosure were evaluated using a biochemical assay using the ADP-Glo technology. ADP-Glo (Promega, Madison, Wis., ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/9/2023
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM594927(US11584758, Compound I-13)
Affinity DataIC50: 25.7nMAssay Description:In this example, compounds of the disclosure were evaluated using a biochemical assay using the ADP-Glo technology. ADP-Glo (Promega, Madison, Wis., ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/9/2023
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM594939(US11584758, Compound I-25 | US11584758, Compound I...)
Affinity DataIC50: 26nMAssay Description:In this example, compounds of the disclosure were evaluated using a biochemical assay using the ADP-Glo technology. ADP-Glo (Promega, Madison, Wis., ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/9/2023
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM594937(US11584758, Compound I-23)
Affinity DataIC50: 26.1nMAssay Description:In this example, compounds of the disclosure were evaluated using a biochemical assay using the ADP-Glo technology. ADP-Glo (Promega, Madison, Wis., ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/9/2023
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM594939(US11584758, Compound I-25 | US11584758, Compound I...)
Affinity DataIC50: 26.5nMAssay Description:In this example, compounds of the disclosure were evaluated using a biochemical assay using the ADP-Glo technology. ADP-Glo (Promega, Madison, Wis., ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/9/2023
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM594948(US11584758, Compound I-34)
Affinity DataIC50: 26.9nMAssay Description:In this example, compounds of the disclosure were evaluated using a biochemical assay using the ADP-Glo technology. ADP-Glo (Promega, Madison, Wis., ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/9/2023
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM594938(US11584758, Compound I-24)
Affinity DataIC50: 29.1nMAssay Description:In this example, compounds of the disclosure were evaluated using a biochemical assay using the ADP-Glo technology. ADP-Glo (Promega, Madison, Wis., ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/9/2023
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM594961(US11584758, Compound I-47)
Affinity DataIC50: 32.1nMAssay Description:In this example, compounds of the disclosure were evaluated using a biochemical assay using the ADP-Glo technology. ADP-Glo (Promega, Madison, Wis., ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/9/2023
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM594950(US11584758, Compound I-36)
Affinity DataIC50: 33.5nMAssay Description:In this example, compounds of the disclosure were evaluated using a biochemical assay using the ADP-Glo technology. ADP-Glo (Promega, Madison, Wis., ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/9/2023
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM594922(US11584758, Compound I-8)
Affinity DataIC50: 34nMAssay Description:In this example, compounds of the disclosure were evaluated using a biochemical assay using the ADP-Glo technology. ADP-Glo (Promega, Madison, Wis., ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/9/2023
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM594962(US11584758, Compound I-48)
Affinity DataIC50: 34.4nMAssay Description:In this example, compounds of the disclosure were evaluated using a biochemical assay using the ADP-Glo technology. ADP-Glo (Promega, Madison, Wis., ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/9/2023
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM356271(US9815850, Compound 169 | US9815850, Compound 42 |...)
Affinity DataIC50: 37.5nMAssay Description:In this example, compounds of the disclosure were evaluated using a biochemical assay using the ADP-Glo technology. ADP-Glo (Promega, Madison, Wis., ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/9/2023
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM594951(US11584758, Compound I-37)
Affinity DataIC50: 37.7nMAssay Description:In this example, compounds of the disclosure were evaluated using a biochemical assay using the ADP-Glo technology. ADP-Glo (Promega, Madison, Wis., ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/9/2023
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM356408(US9815850, Compound 146 | US9896458, No. 146 | US1...)
Affinity DataIC50: 38nMAssay Description:In this example, compounds of the disclosure were evaluated using a biochemical assay using the ADP-Glo technology. ADP-Glo (Promega, Madison, Wis., ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/9/2023
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM594946(US11584758, Compound I-32)
Affinity DataIC50: 38.1nMAssay Description:In this example, compounds of the disclosure were evaluated using a biochemical assay using the ADP-Glo technology. ADP-Glo (Promega, Madison, Wis., ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/9/2023
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM594924(US11584758, Compound I-10)
Affinity DataIC50: 53.8nMAssay Description:In this example, compounds of the disclosure were evaluated using a biochemical assay using the ADP-Glo technology. ADP-Glo (Promega, Madison, Wis., ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/9/2023
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM594959(US11584758, Compound I-45)
Affinity DataIC50: 59.8nMAssay Description:In this example, compounds of the disclosure were evaluated using a biochemical assay using the ADP-Glo technology. ADP-Glo (Promega, Madison, Wis., ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/9/2023
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM594917(US11584758, Compound I-3)
Affinity DataIC50: 62.7nMAssay Description:In this example, compounds of the disclosure were evaluated using a biochemical assay using the ADP-Glo technology. ADP-Glo (Promega, Madison, Wis., ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/9/2023
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM594921(US11584758, Compound I-7)
Affinity DataIC50: 69.3nMAssay Description:In this example, compounds of the disclosure were evaluated using a biochemical assay using the ADP-Glo technology. ADP-Glo (Promega, Madison, Wis., ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/9/2023
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM594919(US11584758, Compound I-5)
Affinity DataIC50: 72.8nMAssay Description:In this example, compounds of the disclosure were evaluated using a biochemical assay using the ADP-Glo technology. ADP-Glo (Promega, Madison, Wis., ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/9/2023
Entry Details
US Patent

Displayed 1 to 50 (of 60 total ) | Next | Last >>
Jump to: